"Many people with obesity suffer from co-morbidities," said Novo Nordisk's chief science officer Mads Krogsgaard Thomsen, in a statement. "Saxenda has the potential to help some of these people ...
Novo Nordisk accepted back into UK pharma group after ‘sustained improvements’ get suspension lifted
Novo Nordisk has been accepted back into the fold. Two years after suspending Novo, the Association of the British ...
Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...
Researchers have criticised the UK drug industry trade association’s decision to restore Novo Nordisk’s membership despite the company being subject to ongoing regulatory breaches during its two year ...
Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback